drugset / Trial / NCT06295770
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Timeline
- Start
- 2024-06-24
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1 g | Intravenous |